Increased Myosin light chain 9 expression during Kawasaki disease vasculitis

Hironobu Kobayashi1,2,3, Motoko Y Kimura3,4, Ichita Hasegawa3

  • 1Department of Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan.

Frontiers in Immunology
|January 23, 2023
PubMed

Insights

Myosin light chain 9 (Myl9) is elevated in children with Kawasaki disease (KD), a serious vasculitis. Higher Myl9 levels correlate with inflammation and predict response to IVIG therapy, offering a potential biomarker for KD management.

Area of Science:

  • Cardiovascular Research
  • Immunology
  • Pediatric Medicine

Background:

  • Kawasaki disease (KD) is a critical pediatric vasculitis with unknown etiology.
  • Immune response and platelet activation are implicated in KD pathogenesis.
  • Myosin light chain 9 (Myl9), involved in cell contractility and released by platelets, has not been studied in relation to KD.

Purpose of the Study:

  • To investigate the role and clinical significance of Myosin light chain 9 (Myl9) in Kawasaki disease (KD).
  • To assess Myl9 as a potential biomarker for KD inflammation and treatment response.

Main Methods:

  • Measured plasma Myl9 concentrations in KD patients and controls.
  • Evaluated in vitro platelet Myl9 release in KD patients.
  • Assessed Myl9 expression in mouse models of KD vasculitis and human autopsy tissues.

Main Results:

  • Plasma Myl9 levels were significantly higher in acute KD patients versus controls.
  • Myl9 levels decreased with IVIG therapy in responders but not non-responders.
  • Elevated Myl9 expression was found in mouse and human cardiac tissues, preceding inflammation in mice.

Conclusions:

  • Myosin light chain 9 (Myl9) expression is significantly increased in Kawasaki disease (KD) vasculitis.
  • Plasma Myl9 may serve as a valuable biomarker for assessing KD inflammation and predicting IVIG responsiveness.
Abstract